CF
BBNX

Corebridge Financial’s Beta Bionics BBNX Stock Holding History

Corebridge Financial’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,485
Closed -$79.4K – 2982
2025
Q1 		$79.4K Buy
+6,485
New +$121K ﹤0.01% 2557

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Corebridge Financial's BBNX Position: Q2 2025 in Review

Corebridge Financial sold out of Beta Bionics (BBNX) in Q2 2025, closing a stake of 6,485 shares — an estimated $79.4K sold.

Corebridge Financial first reported a position in BBNX in Q1 2025 and held it in 1 quarter. The position peaked at $79.4K in Q1 2025. 116 funds tracked by Wall St. Rank hold BBNX as of Q2 2025.

  • Corebridge Financial reported no remaining Beta Bionics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 6,485 Beta Bionics shares in Q2 2025, an estimated $79.4K.
  • Corebridge Financial first reported a position in Beta Bionics in Q1 2025 and held it in 1 quarter.
  • Corebridge Financial's Beta Bionics position peaked at $79.4K in Q1 2025.
  • 116 funds tracked by Wall St. Rank held Beta Bionics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.